Floatz logo

Tumor Antigen Loaded Autologous Dendritic Cells

Acute Myeloid Leukemia (AML)

University Hospital, AntwerpCell therapyPhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

36 Active assets in the Acute Myeloid Leukemia (AML) cohort.

Asset / SponsorPhaseRating
Dcp-001
Mendus
Phase 2B
CHLORAMBUCIL
Clavis Pharma
Phase 3B
HUMAN HEMATOPOIETIC PROGENITOR CELL, MARROW DERIVED
Hannover Medical School
Phase 3B
Blinatumomab
Ascentage Pharma Group Inc.
Phase 2B
Axitinib
Pfizer
Phase 2B

View all 50 →

Same molecule, other indications

Tumor Antigen Loaded Autologous Dendritic Cells is also rated in:

melanomaDormant
CCC
Indicative ·
51 / 100
View asset →
renal cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
hepatocellular carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →